Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615949 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
A Phase 2 study, sponsored by Cardiol Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04615949 is a Phase 2 study that was terminated before completion, run by Cardiol Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT04615949, a Phase 2 study, was terminated before completion, sponsored by Cardiol Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
Interventions
- DRUG Placebo
- DRUG Cannabidiol, pharmaceutically produced with < 5 ppm THC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2022-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04615949
The ClinicalTrials.gov registry entry for NCT04615949 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardiol Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04615949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04615949 about?
NCT04615949 is a clinical study titled "Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors". Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
What is the current status of trial NCT04615949?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2021-04-30. Estimated completion is 2022-11-30.
What interventions are being tested in trial NCT04615949?
The interventions under investigation include: Placebo (DRUG), Cannabidiol, pharmaceutically produced with < 5 ppm THC (DRUG).
Who is sponsoring clinical trial NCT04615949?
This trial is sponsored by Cardiol Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.